The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-28 and is reviewed periodically as new material appears.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
== Nomenclature == This enzyme is a transferase, specifically one transferring phosphorus-containing groups (phosphotransferases) with a phosphate group as acceptor. The systematic name of this enzyme class is ATP:(d)GMP phosphotransferase. Other names in common use include"
Although the treaty was intended to save the union, hardliners feared that it would encourage some of the smaller republics to follow the lead of Lithuania and press for full independence. On 18 August, the hardliners took control of the government after confining Gorbachev in his Crimean dacha in order to stop him from returning to Moscow to sign the treaty. The August Coup collapsed in the face of overwhelming opposition not only from the smaller republics but from larger ones, especially Russia. The treaty was ultimately not signed, and the Belovezha Accords signed on 8 December 1991 by Russia, Ukraine, and Belarus marked the official dissolution of the Soviet Union, converting the republics into independent states. The leaders of the republics organized the Commonwealth of Independent States, an organization of 12 newly independent states, created to replace the Soviet Union. The Baltic states never joined the CIS. Georgia was not a member until 1993 and withdrew in 2008 following the Russo-Georgian War. Ukraine, which never formally became a member, ended its participation in CIS statutory bodies in 2018 due to the Russo-Ukrainian War.
=== 2010 and beyond === By around 2010, Hanmi's R&D had two areas of interest: developing longer-lasting peptide and protein therapeutics using its "Lapscovery" technology, and developing small molecule tyrosine-kinase inhibitors for cancer and autoimmune diseases. Its strategy was to developmental incremental modifications of existing drugs, create new combination drugs, and to develop novel drugs. In August 2014 Hanmi exclusively licensed rights in China for poziotinib, a small molecule EGFR inhibitor, to the Chinese company Luye Pharma; in February 2015 Hanmi licensed rights in the rest of the world outside of South Korea to Spectrum Pharmaceuticals. In March 2015 Hanmi and Lilly signed an exclusive license outside of Asia for Hanmi's small molecule Bruton's tyrosine kinase inhibitor in the field of autoimmune diseases; Lilly paid $50 million upfront and the deal included up to $640 million in milestones and royalties greater than 10%. In November 2015 Hanmi signed three agreements:
== Renal == In addition to increasing the risk of kidney cancer, smoking can also contribute to additional kidney damage. Smokers are at a significantly increased risk for chronic kidney disease than non-smokers. A history of smoking encourages the progression of diabetic nephropathy.
=== 13 April === The BBC reported that the UK plans to send a third Westland Sea King helicopter to Ukraine in the "coming weeks", with the Ukrainian crew being trained in its maintenance at a base in "southern England".
Sources: en.wikipedia.org
=== Cancer treatment side effects === LLLT has been studied as a way to reduce pain and swelling in breast-cancer related lymphedema. The 2015 systematic review and meta-analysis by Smoot, Chiavola-Larson, et al found "Moderate-strength evidence supports LLLT in the management of [breast cancer related lymphoedema], with […] reductions in volume and pain immediately after conclusion of LLLT treatments. Greater reductions in volume [of lymph nodes or surrounding tissues] were found with the use of LLLT than in treatments without it."
An important microstructural feature of a polymer is its architecture and shape, which relates to the way branch points lead to a deviation from a simple linear chain. A branched polymer molecule is composed of a main chain with one or more substituent side chains or branches. Types of branched polymers include star polymers, comb polymers, polymer brushes, dendronized polymers, ladder polymers, and dendrimers. There exist also two-dimensional polymers (2DP) which are composed of topologically planar repeat units. A polymer's architecture affects many of its physical properties including solution viscosity, melt viscosity, solubility in various solvents, glass-transition temperature and the size of individual polymer coils in solution. A variety of techniques may be employed for the synthesis of a polymeric material with a range of architectures, for example living polymerization.
== Applications == Dry shippers serve various sectors in both the scientific and medical arenas. In the realm of reproductive medicine, these containers facilitate the transportation of delicate biological entities, including human ova and embryos. Within the research landscape, they are employed to carry materials such as spermatozoa or preimplantation embryos of genetically modified mouse strains, safeguarding the integrity and viability of these research assets during their journey. Moreover, biobanks, which archive diverse biological specimens for subsequent scientific exploration, utilize dry shippers to dispatch and acquire samples from researchers worldwide.
== 1950s == South Africa's isolation in sport began in the mid-1950s and increased throughout the 1960s. Apartheid forbade multiracial sport, which meant that overseas teams, by virtue of their having players of diverse races, could not play in South Africa. In 1956, the International Table Tennis Federation severed its ties with the all-white South African Table Tennis Union, preferring the non-racial South African Table Tennis Board. The apartheid government responded by confiscating the passports of the Board's players so that they were unable to attend international games. In April 2010 it was revealed by Muru Walters that in 1956 Ernest Corbett, Minister of Māori Affairs, had told the Māori All Blacks to deliberately lose to the Springboks "for the future of rugby". The Māori team lost 37–0. This was followed by Walters calling for the New Zealand government to apologise for the way it treated Māori rugby players.
Sources: en.wikipedia.org
== Properties == Many properties of single-walled carbon nanotubes depend significantly on the (n,m) type, and this dependence is non-monotonic (see Kataura plot). In particular, the band gap can vary from zero to about 2 eV and the electrical conductivity can show metallic or semiconducting behavior.
Brian Clarke, Artist. For services to Art. Ronald Dennis, , Chair, Podium Analytics and Patron, Tommy's Campaign. For services to Industry and to Charity. Gregory Doran, lately Artistic Director, Royal Shakespeare Company. For services to the Arts. Athelstan Joseph Michael Eavis, , Founder and Leader, Glastonbury Festival. For services to Music and to Charity. Professor William John Edmunds, , Professor, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine. For services to Epidemiology. John Patrick Griffin, Founder, Addison Lee. For services to Business and to Charity. Stephen Alan Michael Hester, Chair, Easyjet and Chair, Nordea. For services to Business and to the Economy. David Charles Holmes, , Chief Executive Officer, Family Action. For services to Children and Families. Professor Amritpal Singh Hungin, , Emeritus Professor of General Practice, Newcastle University. For services to Medicine. Professor John Peter Iredale, , lately Interim Executive Chair, Medical Research Council. For services to Medical Research. The Right Honourable Sajid Javid, , Member of Parliament for Bromsgrove. For Political and Public Service. Timothy Randall Martin, Founder and Chair, Wetherspoons. For services to Hospitality and to Culture. Professor Alexander McCall Smith, , Author and Academic. For services to Literature, to Academia and to Charity Professor Neil James McCready Mortensen, lately President, Royal College of Surgeons of England. For services to Surgery. Gerald Maurice Ronson, , For services to Philanthropy and to the Jewish Community.
To qualify for protection under the FCA, the whistleblower must demonstrate that they were engaged in FCA-protected activity and that the employer knew their activity was protected under the FCA, which presents a challenge for whistleblowers who merely report regulatory violations. To be protected under the FCA, they must reasonably believe the regulatory noncompliance has or will amount to fraud against the government, and they must put the employer on notice that their protected activity relates to the filing of false or fraudulent claims. Laboratory workers who merely report CLIA violations without tying the issues to Medicare or Medicaid reimbursement are unlikely to receive FCA whistleblower protection. From 2004-2005, approximately 460 patients Maryland General Hospital were tested for Hepatitis C and HIV with invalid controls. Follow-up retesting was not possible as many patients were unreachable due to being homeless. The incident prompted CAP to add whistleblower protections. In September 2015, a Theranos employee emailed a complaint to the Centers for Medicare and Medicaid Services (CMS) outlining regulatory noncompliance, which led to the company's exposure as a fraud and subsequent downfall.
=== Mixed with polyketides === Due to the similarity with polyketide synthases (PKS), many secondary metabolites are, in fact, fusions of NRPs and polyketides. In essence, this occurs when PK modules follow NRP modules, and vice versa. This is possible because the carrier domains (PCP/ACP) are quite similar between each other and they use a similar "chain-flipping" action to access the growing substrate. Although there is high degree of similarity between the Carrier (PCP/ACP) domains of both types of synthetases, the mechanism of condensation is different from a chemical standpoint:
Two isolated fossilized footprints have been tentatively assigned to T. rex. The first was discovered at Philmont Scout Ranch, New Mexico, in 1983 by American geologist Charles Pillmore. Originally thought to belong to a hadrosaurid, examination of the footprint revealed a large 'heel' unknown in ornithopod dinosaur tracks, and traces of what may have been a hallux, the dewclaw-like fourth digit of the tyrannosaur foot. The footprint was published as the ichnogenus Tyrannosauripus pillmorei in 1994, by Martin Lockley and Adrian Hunt. Lockley and Hunt suggested that it was very likely the track was made by a T. rex, which would make it the first known footprint from this species. The track was made in what was once a vegetated wetland mudflat. It measures 83 centimeters (33 in) long by 71 centimeters (28 in) wide. A second footprint that may have been made by a Tyrannosaurus was first reported in 2007 by British paleontologist Phil Manning, from the Hell Creek Formation of Montana. This second track measures 72 centimeters (28 in) long, shorter than the track described by Lockley and Hunt. Whether or not the track was made by Tyrannosaurus is unclear, though Tyrannosaurus is the only large theropod known to have existed in the Hell Creek Formation. A set of footprints in Glenrock, Wyoming dating to the Maastrichtian stage of the Late Cretaceous and hailing from the Lance Formation were described by Scott Persons, Phil Currie and colleagues in 2016, and are believed to belong to either a juvenile T. rex or Nanotyrannus lancensis.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.